173 related articles for article (PubMed ID: 35833296)
41. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
[TBL] [Abstract][Full Text] [Related]
42. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
[TBL] [Abstract][Full Text] [Related]
43. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.
Liu M; Li Z; Yao W; Zeng X; Wang L; Cheng J; Ma B; Zhang R; Min W; Wang H
Mol Med Rep; 2020 Jan; 21(1):445-453. PubMed ID: 31746428
[TBL] [Abstract][Full Text] [Related]
44. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
45. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.
Nagasaki J; Togashi Y; Sugawara T; Itami M; Yamauchi N; Yuda J; Sugano M; Ohara Y; Minami Y; Nakamae H; Hino M; Takeuchi M; Nishikawa H
Blood Adv; 2020 Sep; 4(17):4069-4082. PubMed ID: 32870971
[TBL] [Abstract][Full Text] [Related]
46. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
47. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
48. Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment.
Post GR; Yuan Y; Holthoff ER; Quick CM; Post SR
PLoS One; 2019; 14(11):e0224621. PubMed ID: 31714922
[TBL] [Abstract][Full Text] [Related]
49. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
50. Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation.
Chen Y; Huang Y; Lu X; Wang G; Chi P
Oncol Rep; 2018 Dec; 40(6):3370-3380. PubMed ID: 30272332
[TBL] [Abstract][Full Text] [Related]
51. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.
Le-Nguyen A; Rys RN; Petrogiannis-Haliotis T; Johnson NA
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1432. PubMed ID: 34047076
[TBL] [Abstract][Full Text] [Related]
52. CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.
Zhou Q; Xiong W; Zhou X; Gao RS; Lin QF; Liu HY; Li JN; Tian XF
Mol Med Rep; 2019 Nov; 20(5):4244-4252. PubMed ID: 31545446
[TBL] [Abstract][Full Text] [Related]
53. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
Wang YL; Gong Y; Lv Z; Li L; Yuan Y
J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
[No Abstract] [Full Text] [Related]
54. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
55. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
56. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
[TBL] [Abstract][Full Text] [Related]
57. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
[TBL] [Abstract][Full Text] [Related]
58. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
59. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Lei Q; Wang D; Sun K; Wang L; Zhang Y
Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
[TBL] [Abstract][Full Text] [Related]
60. CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma.
Veldman J; Rodrigues Plaça J; Chong L; Terpstra MM; Mastik M; van Kempen LC; Kok K; Aoki T; Steidl C; van den Berg A; Visser L; Diepstra A
Oncoimmunology; 2022; 11(1):2033433. PubMed ID: 35111387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]